Frontiers in Aging Neuroscience

Frontiers in Aging Neuroscience is a multidisciplinary open-access journal published by Frontiers Media in Lausanne, Switzerland, since 2009, devoted to the mechanistic biology of central nervous system ageing and age-related neurological disease, with a 2025 Journal Impact Factor of 5.2 and a CiteScore of 10.0.《衰老神经科学前沿》（Frontiers in Aging Neuroscience）是由（Frontiers Media）自 2009 年起在瑞士洛桑出版的开放获取多学科期刊，专注中枢神经系统衰老与年龄相关神经疾病的机制研究，2025 年期刊影响因子为 5.2，CiteScore 为 10.0。

Scope

• Alzheimer's disease and related dementias form the journal's largest clinical strand, spanning biomarkers, neuroimaging, proteinopathy and mechanistically framed trial work.阿尔茨海默病及相关痴呆是刊物最大的临床板块，涵盖生物标志物、神经影像、蛋白病理性改变以及与临床试验相衔接的机制研究。
• Cellular and molecular mechanisms of brain ageing are a second pillar, from mitochondrial and proteostatic decline to glial senescence and cerebrovascular ageing.脑衰老的细胞与分子机制是第二大支柱，涉及线粒体功能与蛋白稳态衰退、胶质细胞衰老以及脑血管老化。
• Neurocognitive ageing and behaviour are studied through cognitive neuroscience, neuropsychology and lifespan work on memory, attention and decision making.神经认知老化与行为板块借助认知神经科学、神经心理学以及记忆、注意与决策的毕生发展研究展开。
• Neuroinflammation and neuropathy have a dedicated section covering immune signalling, blood-brain barrier failure, prion-like propagation and peripheral nerve ageing.神经炎症与神经病变设有独立栏目，覆盖免疫信号、血脑屏障失效、类朊病毒样传播以及周围神经老化。
• Parkinson's disease and ageing-related movement disorders are treated from synuclein biology and genetics through to deep brain stimulation and rehabilitation.帕金森病与年龄相关运动障碍从突触核蛋白生物学与遗传学一直讨论到脑深部刺激与康复治疗。
• Ageing may be approached through genetic, biophysical, genomic, proteomic, cellular, molecular, biochemical, endocrinal, immunological, physiological, pharmacological or psychological and behavioural lenses, and mechanistic neuroimaging and clinical studies are equally welcome.衰老可从遗传、生物物理、基因组、蛋白质组、细胞、分子、生化、内分泌、免疫、生理、药理以及心理与行为等角度切入，以机制为目标的神经影像与临床研究同样受欢迎。
• Purely clinical, theoretical or epidemiological papers, purely statistical studies, and work lacking a mechanistic link to age-related processes fall outside the scope, while computational analyses of public data must carry appropriate validation.纯临床、纯理论或纯流行病学论文、纯统计分析，以及缺乏与衰老过程机制联系的研究均不在收稿范围之内，基于公开数据的计算分析则须提供充分验证。

History

• The journal opened in 2009 as one of the early specialty titles of the Frontiers platform, publishing article by article rather than in paginated issues, and its first volume carried the DOI stem 10.3389/neuro.24.本刊于 2009 年作为（Frontiers）平台早期专业刊之一创刊，逐篇在线发表而非按页码结集出版，首卷论文沿用创刊时设定的标识符前缀。
• It appeared online only from the outset, with no print edition, and has kept continuous publication, grouping papers by annual volume instead of monthly issues.本刊自创刊即为纯在线出版，没有印刷版，并一直沿用连续出版模式，按年度卷次而非按月期号归集论文。
• All content appears under CC BY 4.0 with copyright retained by authors, and the article processing charge is 3,150 Swiss francs for A-type articles and 2,500 for B-type articles, with waivers for authors in low-income countries.全部论文以（CC BY 4.0）许可发表，版权归作者所有，文章处理费为 A 类文章 3,150 瑞士法郎、B 类文章 2,500 瑞士法郎，低收入国家作者可申请减免。
• The title is indexed in PubMed Central, Scopus and the Science Citation Index Expanded, and is listed in the Directory of Open Access Journals, which records open access publication from 2009.本刊被（PubMed Central）、（Scopus）与科学引文索引扩展版收录，并列入开放获取期刊目录（DOAJ），该目录记载其开放获取起始年为 2009 年。
• The 2025 Journal Impact Factor is 5.2, after 4.5 in 2024, 5.702 in 2022 and 5.75 in 2021, with a CiteScore of 10.0 and more than 231,000 citations counted by the publisher, across roughly 8,500 published articles.2025 年期刊影响因子为 5.2，2024 年为 4.5，2022 年为 5.702，2021 年为 5.75；CiteScore 为 10.0，出版方统计的引用总数超过 231,000 次，已发表论文约 8,500 篇。
• In the 2025 Journal Citation Reports it sits in the first quartile of both Neurosciences, at 65 of 330, and Geriatrics and Gerontology, at 15 of 72.在 2025 年期刊引用报告中，本刊在神经科学（330 种中列第 65）与老年医学及老年学（72 种中列第 15）两个类别均居一区。

Editors

• Thomas Wisniewski of the Grossman School of Medicine at New York University is Field Chief Editor, with a research focus on neurodegenerative disease and protein misfolding.纽约大学格罗斯曼医学院（Grossman School of Medicine，New York University）的（Thomas Wisniewski）任总主编，研究方向为神经退行性疾病与蛋白质错折叠。
• Oscar Arias-Carrión of the National Institute of Rehabilitation Luis Guillermo Ibarra Ibarra in Mexico City leads the Parkinson's disease and ageing-related movement disorders section.墨西哥城路易斯·吉列尔莫·伊瓦拉康复研究所（National Institute of Rehabilitation Luis Guillermo Ibarra Ibarra）的（Oscar Arias-Carrión）主持帕金森病与年龄相关运动障碍栏目。
• Sandra Baez of the University of Los Andes in Bogotá heads the Alzheimer's disease and related dementias section, and Yu-Min Kuo of National Cheng Kung University in Tainan heads neuroinflammation and neuropathy.波哥大洛斯安第斯大学（University of Los Andes）的（Sandra Baez）主持阿尔茨海默病及相关痴呆栏目，台南成功大学（National Cheng Kung University）的（Yu-Min Kuo）主持神经炎症与神经病变栏目。
• Review is collaborative rather than sequential, with authors and reviewers debating a manuscript in one online forum until a consensus report reaches the handling editor.评审采用协作式而非串行方式，作者与审稿人在同一在线论坛中就稿件往复讨论，直至形成共识意见并提交给责任编辑。
• Reviewers follow a structured questionnaire focused on soundness rather than perceived impact, and their names are printed alongside accepted articles.审稿人依据结构化问卷评估，重在结论是否可靠而非预估影响力，审稿人姓名随录用论文一并公布。
• Authors may name a preferred Associate Editor, while community reviewers self-assign manuscripts and are vetted by associate, specialty and field chief editors.作者可提名希望处理稿件的副编辑，社区审稿人则自行认领稿件，其资格由副编辑、栏目主编与总主编逐级审核。
• Before review the AIRA integrity tool runs more than fifty checks for plagiarism, image manipulation and fabricated content, and article types are priced and handled in three tiers, A, B and C.送审之前，AIRA 科研诚信工具执行五十余项检查，覆盖抄袭、图像操纵与内容伪造；文章类型按 A、B、C 三档分别定价与处理。